On Nov. 19 the U.S. Food and Drug Administration (FDA) approved Navigator for treating equine protozoal myeloencephalitis (EPM). This drug has been under development for more than six years.

IDEXX Laboratories of Westbrook, Maine, received approval for the 32% nitazoxanide antiprotozoal oral paste designed to kill the single-celled protozoan parasite Sarcocystis neurona, which

To continue reading this article, become a member of TheHorse.com.

It's FREE and you'll get full access to more than 20,000 articles, video, free reports & more.

Sign In
Stay on top of the most recent Horse Health news with FREE weekly newsletters from TheHorse.com. Learn More

Free Newsletters

Sign up for the latest in:

From our partners